Suppr超能文献

健康受试者中螺内酯的剂量-反应关系。

Spironolactone dose-response relationships in healthy subjects.

作者信息

McInnes G T, Perkins R M, Shelton J R, Harrison I R

出版信息

Br J Clin Pharmacol. 1982 Apr;13(4):513-8. doi: 10.1111/j.1365-2125.1982.tb01413.x.

Abstract

1 The effect of single oral doses of spironolactone 25 mg, 50 mg, 100 mg, 200 mg, 400 mg, and placebo in reversing the urinary electrolyte changes induced by fludrocortisone between 2-10 h and 12-16 h after treatment was examined in healthy subjects. 2 In the two collection periods, there were statistically significant log linear dose-response relationships for sodium excretion (P less than 0.001), potassium excretion (P less than 0.001 and P less than 0.025 respectively) and log10 10 Na/K (P less than 0.001). 3 However, there was evidence that the log spironolactone dose-urinary sodium responses did not increase monotonically, while the relationship for urinary potassium appeared to enter the lower 'plateau' at doses between 100 mg and 200 mg, and when compared to placebo values, potassium excretion was not significantly depressed 12-16 h after treatment (P greater than 0.1). Thus, sodium and potassium responses were dissociated in dose producing maximal effect and in duration of activity, reinforcing the view that functions or the urinary sodium/potassium ratio alone cannot be considered an adequate description of renal antimineralocorticoid activity. 4 Dose-response relationships for all urinary electrolyte variables seem consistently steep and linear between 25 mg and 100 mg of spironolactone, suggesting that, in studies employing this model, the doses of spironolactone should be restricted to this range.

摘要

1 在健康受试者中,研究了单次口服25毫克、50毫克、100毫克、200毫克、400毫克螺内酯以及安慰剂对氟氢可的松治疗后2至10小时和12至16小时内尿电解质变化的逆转作用。2 在两个收集期内,钠排泄(P<0.001)、钾排泄(分别为P<0.001和P<0.025)以及log10 Na/K(P<0.001)存在统计学上显著的对数线性剂量反应关系。3 然而,有证据表明,螺内酯剂量与尿钠反应的对数并非单调增加,而尿钾的关系在100毫克至200毫克剂量之间似乎进入较低的“平台期”,并且与安慰剂值相比,治疗后12至16小时钾排泄并未显著降低(P>0.1)。因此,在产生最大效应的剂量和活性持续时间方面,钠和钾的反应是分离的,这进一步支持了仅靠尿钠/钾比值的功能不能被视为对肾脏抗盐皮质激素活性的充分描述这一观点。4 在25毫克至100毫克螺内酯之间,所有尿电解质变量的剂量反应关系似乎始终陡峭且呈线性,这表明在采用该模型的研究中,螺内酯的剂量应限制在这个范围内。

相似文献

1
Spironolactone dose-response relationships in healthy subjects.
Br J Clin Pharmacol. 1982 Apr;13(4):513-8. doi: 10.1111/j.1365-2125.1982.tb01413.x.
2
Dose-response relationships for spironolactone at steady state.
Clin Pharmacol Ther. 1982 Mar;31(3):317-23. doi: 10.1038/clpt.1982.40.
3
Dose-response relationships for spironolactone in combination with a potassium-wasting diuretic.
Clin Pharmacol Ther. 1983 Jan;33(1):35-43. doi: 10.1038/clpt.1983.5.
4
Steady-state relative potency of aldosterone antagonists: spironolactone and prorenoate.
Clin Pharmacol Ther. 1981 May;29(5):679-86. doi: 10.1038/clpt.1981.95.
6
The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects.
Br J Clin Pharmacol. 1976 Jun;3(3):475-82. doi: 10.1111/j.1365-2125.1976.tb00624.x.
7
Relative potency of amiloride and spironolactone in healthy man.
Clin Pharmacol Ther. 1982 Apr;31(4):472-7. doi: 10.1038/clpt.1982.62.
8
Relative potency of prorenoate and spironolactone in normal man.
Clin Pharmacol Ther. 1975 Oct;18(4):391-400. doi: 10.1002/cpt1975184391.

引用本文的文献

3
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone.
J Pharmacokinet Pharmacodyn. 2022 Aug;49(4):471-486. doi: 10.1007/s10928-022-09815-x. Epub 2022 Jul 1.
5
First-in-Man Demonstration of Direct Endothelin-Mediated Natriuresis and Diuresis.
Hypertension. 2017 Jul;70(1):192-200. doi: 10.1161/HYPERTENSIONAHA.116.08832. Epub 2017 May 15.
7
Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy.
Nat Rev Nephrol. 2012 Dec;8(12):691-9. doi: 10.1038/nrneph.2012.217. Epub 2012 Oct 16.
8
Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects.
Br J Clin Pharmacol. 1984 Sep;18(3):369-75. doi: 10.1111/j.1365-2125.1984.tb02478.x.
9
Diuretics. Clinical pharmacology and therapeutic use (Part II).
Drugs. 1985 Feb;29(2):162-88. doi: 10.2165/00003495-198529020-00003.

本文引用的文献

4
The aldosterone blocking effects of spirolactones.
Jpn J Pharmacol. 1962 Mar;11:77-87. doi: 10.1254/jjp.11.77.
6
Aldosterone antagonists.
N Y State J Med. 1961 Mar 1;61:756-70.
7
Sodium diuresis induced by steroidal antagonists of aldosterone.
Science. 1957 Nov 15;126(3281):1016-8. doi: 10.1126/science.126.3281.1016.
8
Activity of sulfur-containing intermediate metabolites of spironolactone.
Clin Pharmacol Ther. 1980 Mar;27(3):363-9. doi: 10.1038/clpt.1980.48.
9
Quantitative comparison of aldosterone antagonists in normal human subjects: prediction of therapeutic potency.
Br J Clin Pharmacol. 1981 Nov;12(5):743-7. doi: 10.1111/j.1365-2125.1981.tb01299.x.
10
Bioassay of a new aldosterone antagonist and evaluation of a simple method of quantitative comparison.
Clin Pharmacol Ther. 1981 Aug;30(2):218-25. doi: 10.1038/clpt.1981.151.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验